Oriola Oyj (ORIOLA.HE)
Full history for every metric is available with a Kvantra account
No price history available.
Key financial summary
Financials in EUR| 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM | 2026E | ||
|---|---|---|---|---|---|---|---|---|---|
| Total revenue | €m | 1,801 | 1,452 | 1,539 | 1,494 | 1,680 | 1,906 | 1,067 | - |
| Operating profit | €m | 7 | 9 | ||||||
| Net profit | €m | 11 | 11 | -2 | -21 | -20 | -27 | -20 | 14 |
| EPS reported | € | -0.15 | -0.11 | ||||||
| Operating cashflow per share | € | 0.33 | 0.03 | ||||||
| Capex per share | € | 0.02 | 0.05 | ||||||
| FCF per share | € | 0.31 | -0.03 | ||||||
| Free cash flow | €m | 57 | -5 | ||||||
| Net debt | €m | -94 | -35 | ||||||
| Book value equity | €m | 101 | 88 | ||||||
| Book value per share | € | 0.55 | 0.48 | ||||||
| Number of shares | m | 184.23 | 185.04 | ||||||
| DPS (TTM paid) | € | 0.03 | 0.03 |
Financial summary
Financials in EUR| 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM | 2026E | ||
|---|---|---|---|---|---|---|---|---|---|
| Value | |||||||||
| P/E TTM | x | - | - | ||||||
| P/B LTM | x | 2.10 | 2.40 | ||||||
| P/S LTM | x | 0.11 | 0.20 | ||||||
| P/FCF LTM | x | 3.74 | -41.54 | ||||||
| EV/EBITDA LTM | x | 6.72 | 5.95 | ||||||
| EV/Sales LTM | x | 0.07 | 0.12 | ||||||
| Earnings Yield LTM | % | -12.84% | -11.81% | ||||||
| FCF Yield | % | +26.76% | -2.41% | ||||||
| Quality | |||||||||
| ROE | % | -26.98% | -19.61% | ||||||
| ROIC | % | +3.89% | +5.05% | ||||||
| Operating margin | % | +0.38% | +0.86% | ||||||
| Gross margin | % | +3.56% | +0.82% | ||||||
| FCF/Sales | % | +2.97% | -0.48% | ||||||
| Growth and momentum | |||||||||
| EPS Growth YoY | % | - | - | ||||||
| Sales Growth YoY | % | +13.48% | -36.48% | ||||||
| Net Income Growth YoY | % | - | - | ||||||
| FCF Growth | % | +57.94% | - | ||||||
| Operating Profit Growth | % | -45.93% | -31.85% | ||||||
| Dividend and capital structure | |||||||||
| Dividend Yield | % | +5.99% | +3.34% | ||||||
| Dividend Growth | % | -57.14% | -57.14% | ||||||
| Payout Ratio | % | -45.96% | -28.58% | ||||||
| FCF/Debt | x | 0.81 | -0.07 | ||||||
| Net Debt/EBITDA | x | -4.26 | -1.59 | ||||||
| EBIT/Net interest | x | 0.99 | 1.30 | ||||||
| Net debt/market cap | % | +27.47% | +42.60% | ||||||
| Net debt/Equity | x | -0.93 | -0.39 | ||||||
| Gross debt/equity | x | 0.69 | 0.88 | ||||||
Ratings
Based on consensus from external analysts. Not Kvantra's opinion.
Company overview
Oriola Oyj, headquartered in Espoo, Finland, and established in 1907, is a leading player in the wholesale distribution of pharmaceuticals and a wide array of health and wellness products across Sweden, Finland, and international markets. Their extensive product portfolio includes vitamins, nutritional supplements, sports-specific items, wound care solutions, beauty and cosmetic goods, vaccines, and over-the-counter medications. Beyond distribution, Oriola provides a comprehensive suite of expert services. These encompass pharmaceutical logistics, specialized import of licensed medicines, personalized dose dispensing, and support for research pharmacies. The company also offers commercial data insights, clinical trial management, regulatory affairs, quality assurance, medical and scientific advisory, market access strategies, real-world evidence generation, sales support, medical translation, pharmacovigilance, medical information, and patient assistance programs, alongside general advisory services. Oriola serves a diverse client base, ranging from pharmaceutical manufacturers and pharmacies to veterinarians, hospitals, healthcare providers, specialty stores, retailers, and e-commerce businesses.
Similar companies
For informational purposes only. Kvantra provides data and quantitative analysis, not investment advice. KvantraRank is a mechanical model output. Analyst price targets and ratings are sourced from third parties and are not Kvantra recommendations. Past performance does not guarantee future results; all investments carry risk.
No price history available.
Based on consensus from external analysts. Not Kvantra's opinion.
Oriola Oyj, headquartered in Espoo, Finland, and established in 1907, is a leading player in the wholesale distribution of pharmaceuticals and a wide array of health and wellness products across Sweden, Finland, and international markets. Their extensive product portfolio includes vitamins, nutritional supplements, sports-specific items, wound care solutions, beauty and cosmetic goods, vaccines, and over-the-counter medications. Beyond distribution, Oriola provides a comprehensive suite of expert services. These encompass pharmaceutical logistics, specialized import of licensed medicines, personalized dose dispensing, and support for research pharmacies. The company also offers commercial data insights, clinical trial management, regulatory affairs, quality assurance, medical and scientific advisory, market access strategies, real-world evidence generation, sales support, medical translation, pharmacovigilance, medical information, and patient assistance programs, alongside general advisory services. Oriola serves a diverse client base, ranging from pharmaceutical manufacturers and pharmacies to veterinarians, hospitals, healthcare providers, specialty stores, retailers, and e-commerce businesses.
Unlock all fundamental data
Sign up for FreeUnlock all fundamental data
Sign up for Free